Pt:62FwithbreastmassleftupperouterquadrantPresenting8/15/2024palpable3.8cmmassUS-guidedcorebiopsyshowed|nvasiveductalcarcinoma,grade3,ER+95%PR+80%HER2:3+byIHC,FISHratio2.8,Ki6785%.Mammogramshowedspiculatedmass+microcalcifications.MRIbreast:4.2cmenhancingmasswithnippleretractionÂ§axiIlarylymphadenopathy.

Staging~workup:CTchest/abdomen/pelvisandbonescanOctober2024showednoevidencemetastaticdisease.Axillarynode~FNA:positiveformetastaticadenocarcinoma2/3corespositive.ClinicalstageT2N1M0,stageIIBbasedonclinicalexam+imaging.

Biomarkers:ER95%Allred8/8|PR80%Allred7/8|HER23+IHC|FISHHer2/CEP17=2.8amplified|Ki6785%|Oncotype~notdone~NodePositive|BRCA1/2~germlinenegative|PIK3CAwildtype

NeoadjuvantTherapyStarted9/20/2024:TCHPregimen(docetaxel+carboplatin+trastuzumab+pertuzumab)Cycle1&2toleratedwellbutCycle3developedgrade3diarrhea~loperamideandfluidIVrequired+Grade2neuropathy(tingling~bilateralfeet)docetaxelreducedto75%dose.Cycle4-6:persistentgrade2neuropathy,furtherdosereduction.RestagingMRI12/2024showedpartialmresponse,residualtumor2.1cmfrom4.2cm.Surgery1/2025:leftmastectomy+axillarydissection

PATHOLOGY|nvasiveductalcarcinoma,1.8cmresidualtumor,grade3ypT1cN2aM0(4/14axillarynodes+,largestdeposit8mm,extracapsularextensionpresent)margins:negativeLVI:presentResidualCancerBurden:RCB-II(moderateresponse)ER88%PR65%HER22+onresidual~possibleHER2loss?repeatFISHpending

PostoperativeManagement:EnrolledinAPHINITY-Btrial(NCT04577677)~randomizedArmB:HP~therapy(trastuzumab+pertuzumab1year)vsArmA:HPplus~tucatinib.Stratifiedbyhormone-receptorpositive,nodepositive,nopCR.Trialstartdate2/10/2025patient#unknown~sitecoordinator:Dr.Mehta

Adjuvant~endocrine:AI~therapy(anastrozole)started2/15/2025,tobe~continuedfor5-10yearsdependingonriskstratification.

3-monthfollow-up5/2025:CTscanshowednewliver~lesion,segment6,1.4cm,concernformetastaticdisease.LiverbiopsyshowedmetastaticbreastadenocarcinomaER+HER2-~HER2lossfromoriginal3+confirmedonmetastasis~Progressiondiseaseon~adjuvanttrial<4monthsfromsurgery.WithdrawnfromAPHINITYtrial.

NewTreatmentPlan:switchedtoCDK4/6inhibitor(palbociclib)+fulvestrant+trastuzumabderuxtecan(T-DXd)forHER2-lowdiseaseStarted6/2025toleratedwell~noimagingyet
